Orap

(Pimozide)

Phase 2Small molecule

Teva

Orap is one of 84 small molecule programs targeting Tourette syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Tourette SyndromeActive, not recruiting

COVID-19Active, not recruiting

SchizophreniaActive, not recruiting

Tourette SyndromePhase 2

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Orap

Teva

Phase 2

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Biaxin

AbbVie

Preclinical

2 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Singulair

AstraZeneca

Preclinical

1 7

Calciferol

Alnylam Pharmaceuticals

Preclinical

—8

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Benadryl

PParkedale

Preclinical

1 10

Nitrostat

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia2 trials

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02600741·296 enrolled

Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT00158223·76 enrolled

Tourette syndrome1 trial

Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004652·20 enrolled

Antipsychotics1 trial

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed·TTechnical University of Munich·Phase 4·NCT02307396·21 enrolled

Partial Response1 trial

Efficacy of Pimozide Augmentation for Clozapine Partial Response

Completed·YYale University·Phase 2·NCT00374244·28 enrolled

Drug1 trial

Electrophysiological Effects of Potential QT Prolonging Drugs

Completed·FFood and Drug Administration (FDA)·Phase 1·NCT05716854·44 enrolled

2 more indications

COVID-191 trial

Treatment for Post Acute COVID-19 Syndrome

Unknown status·AApplied Biology, Inc.·N/A·NCT05507372·50 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 27, 1997

ORAP

NDA NDA017473

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Pimozide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pimozide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pimozide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA017473). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Teva

Orap

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia2 trials

Tourette syndrome1 trial

Antipsychotics1 trial

Partial Response1 trial

Drug1 trial

COVID-191 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News